Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com. Inclusion Criteria * Diagnosis of advanced malignancy, nonsmall-cell lung cancer (NSCLC) only during stage 1 of accrual. * Nonsynonymous mutation of B-RAF or DDR2, defined as follows:. i) NSCLC with inactivating B-RAF mutation. ii) NSCLC with discoidin domain receptor 2 (DDR2) mutation. iii) Malignancy of other histology with DDR2 mutation or inactivating B-RAF mutation, or NSCLC having a B-RAF mutation that is not functionally characterized. * At least 1 target lesion per Response Evaluation Criteria in Solid Tumors, vol 1.1, on baseline staging evaluation. * Disease progression after ≥ 1 prior treatment regimen. Exclusion Criteria * Pleural or pericardial effusion, Grade \>1. * QTcF \>470 msec (Grade ≥2) or diagnosed congenital long QT syndrome. * Absolute granulocyte count \<1500/mm\^3. * Hemoglobin level \<10 g/dL. * Platelet count \< 75,000/mm\^3. * Serum calcium level \<institutional lower limit of normal. * Hypokalemia, hypophosphatemia, or hypomagnesemia, Grade \>1, despite supplementation. * Creatinine \>3\*institutional upper limit of normal (ULN). * Total bilirubin level \>1.5\*ULN. * Alanine transaminase level \>3\*ULN. * Other protocol-defined Inclusion/Exclusion criteria apply.